针对急性期神经贝赫塞病的无皮质类固醇阿达利穆马布-cyclophosphamide组合治疗:一个病例报告
Ji Hyoun Kim1, Sang Wan Chung2, Yun Jong Lee3,4
1Division of Rheumatology, Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea.
Journal of rheumatic diseases
|July 3, 2024
概括
一种新的阿达利穆马布-环胺组合为神经贝赫塞特病 (NBD) 提供了无皮质类固醇的诱导疗法. 这种方法在NBD患者中预防了新的病变和复发,表明了有前途的替代治疗策略.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 眼科医生 眼科 眼科
背景情况:
- 神经贝希特病 (NBD) 是贝希特综合征的严重并发症,通常用高剂量的皮质类固醇和免疫抑制剂治疗.
- 标准治疗可能会导致不良反应,例如眼内压力升高和玻璃眼的恶化,正如本案所示.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
114
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
114
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
128
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
128
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
156
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
156
Inflammatory Bowel Disease IV: Pharmacological Management
125
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
125
Drugs for Treatment of Ulcerative Colitis in IBD
134
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
134
Alzheimer's Disease: Treatment
177
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
177


